TherapeuticsMD (TXMD) AI Stock Analysis

2,250 Followers

TherapeuticsMD

(NASDAQ:TXMD)

Select Model

Rating:44Neutral

Price Target:$2.00▲(6.95% Upside)

Action:reiterated

Date:11/14/26

TXMD scores low primarily because of its extremely small financial scale and lack of operating profitability — TTM revenue of just $3.3M after a ~98% revenue collapse, with a deeply negative EBIT margin and a negative P/E. Technicals reinforce caution, with the price below its 50-, 100- and 200-day moving averages and a negative MACD. Partially offsetting these risks are a substantially de-risked balance sheet (debt down to $5.6M, equity restored to $27.1M), positive and improving operating cash flow, and an encouraging Q3 2026 report showing net income of $501K and 60.6% license revenue growth. The business is stabilizing as a royalty vehicle, but until revenue scale and durable profitability emerge, the risk profile remains elevated.

Positive Factors

Positive Cash GenerationPositive operating and free cash flow mark a meaningful turnaround from deeply negative operating cash flow in 2023. This improves internal funding capacity and provides greater resilience as TherapeuticsMD manages its licensing portfolio, although it does not yet establish durable profitability.

Negative Factors

Weak Operating FundamentalsThe current revenue base remains too small to support the operating cost structure, leaving EBIT and EBITDA materially negative. Until revenue becomes larger and more consistent, the business has limited evidence of sustainable earnings power and remains exposed to volatility in licensing receipts.

TherapeuticsMD (TXMD) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $21.07M
Dividend Yield: ―
Average Volume (3M): 24.41K
Price to Earnings (P/E): 230.9
Beta (1Y): 1.17
Revenue Growth: 27.78%
EPS Growth: 52.88%
Country: US
Employees: 1
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

TherapeuticsMD Business Overview & Revenue Model

Company Description

TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradi...

How the Company Makes Money

TherapeuticsMD has generated revenue primarily through out-licensing/partnering arrangements for its product portfolio rather than through building a fully integrated, long-term direct commercial sales model. Under these types of agreements, the comp...

TherapeuticsMD Financial Statement Overview

Summary

TherapeuticsMD scores weakly on fundamentals, driven primarily by a very poor income statement (25) following the near-total revenue collapse from $70M in 2022 to just $3.3M TTM. The company remains unprofitable at the operating level with a TTM EBIT margin of -142%, though net losses have narrowed to only -$217K TTM. The balance sheet (55) is the relative bright spot: debt has been cut from $197.7M in 2021 to $5.6M, equity has swung from -$93.6M to a positive $27.1M, and debt-to-equity is a conservative 0.20. Cash flow (48) has turned positive, with $3.1M TTM operating cash flow versus a -$48.1M outflow in 2023, but the absolute amounts are tiny. Overall, the trajectory is encouraging but the business lacks scale and sustained profitability.

Income Statement

25Negative

Balance Sheet

55Neutral

Cash Flow

48Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	3.27M	3.02M	1.76M	1.30M	69.96M	2.57M
Gross Profit	2.94M	3.02M	1.76M	1.30M	68.57M	1.17M
EBITDA	-3.96M	-3.02M	-4.33M	-7.60M	11.86M	-78.84M
Net Income	-217.00K	-569.00K	-2.18M	-10.28M	112.00M	-172.41M
Balance Sheet
Total Assets	37.53M	37.66M	38.82M	43.31M	90.46M	169.47M
Cash, Cash Equivalents and Short-Term Investments	9.19M	7.48M	5.06M	4.33M	38.07M	64.91M
Total Debt	5.56M	6.10M	7.17M	8.01M	8.76M	197.69M
Total Liabilities	10.40M	10.78M	11.45M	14.02M	55.31M	263.09M
Stockholders Equity	27.13M	26.88M	27.37M	29.29M	35.14M	-93.62M
Cash Flow
Free Cash Flow	3.12M	2.42M	732.00K	0	-4.43M	-147.84M
Operating Cash Flow	3.12M	2.42M	732.00K	-48.14M	-4.08M	-147.81M
Investing Cash Flow	0	0	0	0	223.48M	-2.22M
Financing Cash Flow	0	0	0	3.15M	-235.21M	134.67M

TherapeuticsMD Technical Analysis

Technical Analysis SentimentNeutral

Last Price1.87

Price Trends

50DMA1.98Negative

100DMA2.03Negative

200DMA2.09Negative

Market Momentum

MACD-0.06Negative

RSI46.90Neutral

STOCH78.77Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXMD, the sentiment is Neutral. The current price of 1.87 is above the 20-day moving average (MA) of 1.81, below the 50-day MA of 1.98, and below the 200-day MA of 2.09, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 46.90 is Neutral, neither overbought nor oversold. The STOCH value of 78.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TXMD.

TherapeuticsMD Risk Analysis

TherapeuticsMD disclosed 49 risk factors in its most recent earnings report. TherapeuticsMD reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

TherapeuticsMD Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TXMD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	61Neutral	$19.45M	-1.30	-52.89%	―	-13.27%	27.11%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TXMD	44Neutral	$21.07M	230.86	-0.80%	―	27.78%	52.88%
RDHL	42Neutral	$3.39M	-0.38	-438.17%	―	―	―
PRPH	41Neutral	$83.35K	-0.00	-1358.66%	―	―	―

* Healthcare Sector Average

Performance Comparison

TXMD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TXMD	Therapeuticsmd Inc	1.87	0.35	23.03%
PRPH	Prophase Labs	0.01	-2.64	-99.62%
RDHL	RedHill Biopharma Ltd	0.38	-0.67	-63.94%
AYTU	Aytu BioScience	1.78	-0.20	-10.10%
GELS	Gelteq Limited	0.38	-0.56	-59.57%

TherapeuticsMD Corporate Events

Financial Disclosures

TherapeuticsMD Reports Third-Quarter Net Income and Revenue Growth

Positive

Nov 13, 2026

TherapeuticsMD is a pharmaceutical royalty company that primarily collects royalties from licensees; it changed from a women’s healthcare company in December 2022 and no longer engages in research and development or commercial operations. On November...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026

TherapeuticsMD AI Stock Analysis